Fabrice Branle

3.1k total citations
36 papers, 1.5k citations indexed

About

Fabrice Branle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Fabrice Branle has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 8 papers in Genetics. Recurrent topics in Fabrice Branle's work include Lung Cancer Research Studies (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Fabrice Branle is often cited by papers focused on Lung Cancer Research Studies (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Fabrice Branle collaborates with scholars based in Switzerland, Belgium and France. Fabrice Branle's co-authors include Thierry Berghmans, Marianne Paesmans, Anne‐Pascale Meert, Jean‐Paul Sculier, F. Lemaı̂tre, Elizabeth Steels, Frédéric Vallot, Céline Mascaux, J.J. Lafitte and Tony Mok and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Fabrice Branle

35 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabrice Branle Switzerland 15 951 796 578 219 209 36 1.5k
Dana T. Aftab United States 20 882 0.9× 574 0.7× 803 1.4× 182 0.8× 417 2.0× 45 1.8k
Puyuan Xing China 22 1.2k 1.2× 1.0k 1.3× 461 0.8× 151 0.7× 295 1.4× 149 1.7k
Roberta Caputo Italy 13 805 0.8× 664 0.8× 612 1.1× 94 0.4× 317 1.5× 27 1.4k
Chiara Lazzari Italy 24 883 0.9× 738 0.9× 580 1.0× 104 0.5× 313 1.5× 67 1.5k
Adrian Langleben Canada 17 725 0.8× 416 0.5× 316 0.5× 167 0.8× 158 0.8× 55 1.1k
Sophia Abraham United States 8 569 0.6× 491 0.6× 832 1.4× 80 0.4× 201 1.0× 12 1.6k
Zhenfan Yang China 19 1.1k 1.1× 1.2k 1.5× 549 0.9× 57 0.3× 308 1.5× 39 1.8k
Katherine E. Hutchinson United States 19 920 1.0× 536 0.7× 972 1.7× 152 0.7× 595 2.8× 48 1.8k
Philip Bonomi United States 15 593 0.6× 403 0.5× 592 1.0× 140 0.6× 120 0.6× 37 1.2k
Monica Ganzinelli Italy 23 1.2k 1.3× 908 1.1× 710 1.2× 154 0.7× 309 1.5× 83 1.9k

Countries citing papers authored by Fabrice Branle

Since Specialization
Citations

This map shows the geographic impact of Fabrice Branle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrice Branle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrice Branle more than expected).

Fields of papers citing papers by Fabrice Branle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabrice Branle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrice Branle. The network helps show where Fabrice Branle may publish in the future.

Co-authorship network of co-authors of Fabrice Branle

This figure shows the co-authorship network connecting the top 25 collaborators of Fabrice Branle. A scholar is included among the top collaborators of Fabrice Branle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabrice Branle. Fabrice Branle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Canaud, Guillaume, Juan Carlos López‐Gutiérrez, Alan D. Irvine, et al.. (2023). Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genetics in Medicine. 25(12). 100969–100969. 31 indexed citations
2.
Schulte, Johannes H., Lucas Moreno, David S. Ziegler, et al.. (2020). Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).. Journal of Clinical Oncology. 38(15_suppl). 10505–10505. 9 indexed citations
3.
Tan, Daniel S.W., Sarayut Lucien Geater, Chong‐Jen Yu, et al.. (2020). Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. JTO Clinical and Research Reports. 2(3). 100131–100131. 9 indexed citations
4.
Barlési, Fabrice, D.-W. Kim, Erin M. Bertino, et al.. (2019). Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study. Annals of Oncology. 30. v143–v144. 6 indexed citations
5.
Castro, Gilberto de, Daniel Shao-Weng Tan, Lucio Crinò, et al.. (2017). PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). Journal of Thoracic Oncology. 12(1). S7–S7. 8 indexed citations
6.
Tan, Daniel Shao-Weng, Jean‐Charles Soria, Gilberto de Castro, et al.. (2017). P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4). Journal of Thoracic Oncology. 12(1). S1176–S1177. 2 indexed citations
7.
8.
9.
Neyns, Bart, C. Chaskis, E. Joosens, et al.. (2008). A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. Cancer Investigation. 26(3). 269–277. 35 indexed citations
10.
Lecomte, Pascal, Martine Berlière, Fabrice Branle, et al.. (2006). Extended adjuvant letrozole following five years of tamoxifen is cost-effective from a Belgian health care payer's perspective. Ghent University Academic Bibliography (Ghent University). 3 indexed citations
11.
Witte, Olivier De, Nordeyn Oulad Ben Taib, Fabrice Branle, et al.. (2004). Apport de la tomographie à émission de positons dans la prise en charge des gliomes de bas grade. Neurochirurgie. 50(4). 468–473. 6 indexed citations
12.
Everaert, Els, et al.. (2004). Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium. Journal of Neuro-Oncology. 70(1). 37–48. 12 indexed citations
13.
Martin, Benoı̂t, M Paesmans, Thierry Berghmans, et al.. (2003). Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer. 89(1). 55–64. 130 indexed citations
14.
15.
Sculier, Jean‐Paul, T. Berghmans, Marianne Paesmans, et al.. (2001). [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers].. PubMed. 22(6). 477–87. 4 indexed citations
16.
Steels, Elizabeth, Marianne Paesmans, Thierry Berghmans, et al.. (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. European Respiratory Journal. 18(4). 705–719. 337 indexed citations
17.
Piccart, Martine, Fabrice Branle, Dominique de Valeriola, et al.. (2001). A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 36 indexed citations
18.
Mascaux, Céline, Marianne Paesmans, Thierry Berghmans, et al.. (2000). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 30(1). 23–36. 179 indexed citations
19.
Paesmans, Marianne, Thierry Berghmans, Frédéric Vallot, et al.. (2000). Treatment with or without chemotherapy for locally advanced non small cell lung cancer (NSCLC): A systematic review by the European Lung Cancer Working Party. Lung Cancer. 29(1). 90–90.
20.
Meert, Anne‐Pascale, Thierry Berghmans, Fabrice Branle, et al.. (1999). Phase II and III studies with new drugs for non small cell lung carcinoma: a systematic review of the literature with a methodology quality assessment. Lung Cancer. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dana T. Aftab Breakdown of academic impact, for papers by Puyuan Xing Breakdown of academic impact, for papers by Roberta Caputo Breakdown of academic impact, for papers by Chiara Lazzari Breakdown of academic impact, for papers by Adrian Langleben Breakdown of academic impact, for papers by Sophia Abraham Breakdown of academic impact, for papers by Zhenfan Yang Breakdown of academic impact, for papers by Katherine E. Hutchinson Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Monica Ganzinelli
Rankless by CCL
2026